Company intelligence / Profile preview
cellvie
Zurich, Zurich, Switzerlandcellvie.bio ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
cellvie is pioneering a new therapeutic modality—Therapeutic Mitochondria Transplantation—to address diseases caused by mitochondrial dysfunction. The company’s lead programs target ischemia-reperfusion injuries such as those occurring in heart attacks and organ transplants. No published clinical results yet; the technology remains in preclinical or early development stages.[1][2][3]
- Therapeutic areas
- OtherCardiovascularNephrology
- Modalities
- Mitochondria transplantation (cell-derived medicines)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Kizoo Technology Capital [2]Taiho Ventures LLC [2]open to co-development/licensing partnerships in mitochondria therapeutics [1]
Beyond the preview
Go deeper on cellvie.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cellvie.